Resistant strains of the fungus; Aspergillus fumigatus in the environment threaten weak patients.
During the past fifteen years, doctors take patients increasingly the fungus; Aspergillus fumigatus , which is resistant to medical azoles, the main drug to combat the fungus. The mold is everywhere in the environment and poses no threat to people with healthy immune systems. But patients whose immune system in the context of a treatment was switched off – such as certain cancer – are susceptible to the fungus. The same applies to patients with cystic fibrosis (cystic fibrosis) and (ex-) TB patients. An infection with a resistant version of the fungus – which no longer responds to azoles – is downright dangerous because virtually all patients with a disabled immune system that develop such an infection, it can no longer tell the tale. Currently six to thirteen percent of the resistant strains are found in patients. The fact that the drug-resistant fungi were also found in patients who have never been treated previously with azoles proves that there is also already resistant versions of the mold in the environment. The resistance is highly likely to be facilitated because the fungus is exposed to fungicides in agriculture that are based on medical azoles. But possibly also the fact that azoles are used in preservatives, disinfectants, veterinary drugs and consumer products such as paint, cosmetics and mattresses to repel fungus contributes to the growing resistance. biologist Simone Camps of the UMC St Radboud who studied the problem, advocates research on appropriate measures to curb the problem.